BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Stock Information for Entera Bio Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Entera Bio Ltd.

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.